Check Your Claims Before Reviewers Do

 Quick Explanation Copied

 Long Explanation

Scientific Identity and Citation Metrics

Andres Jäschke (ORCID 0000-0002-4625-2655) presents a career-spanning, method-generating research program at the interface of chemistry and RNA biology. OpenAlex indexes 272 works with ~6,719 citations and h-index 46 OpenAlex author profile; Semantic Scholar-derived metrics report h-index 44, 5,627 citations across 192 papers — a discrepancy reflecting database coverage, not quality. Output is sustained (~7–13 works/year through 2025–2026), with citation peaks in 2013–2015 (~480–560/year) tied to the NAD-capping and aptamer-imaging breakthroughs.

Pillar 1: Catalytic Nucleic Acids for C–C Bond Formation

Jäschke's foundational contribution was the discovery and characterization of the Diels–Alderase ribozyme — the first RNA catalyst for a carbon–carbon bond-forming cycloaddition, later shown to be enantioselective (>95% ee) and structurally solved Diels-Alderase ribozyme discovery Diels-Alderase crystal structure. This line — including single-molecule FRET energy-landscape analyses and DNA hybrid catalysts — demonstrates mechanistic depth beyond selection artifacts.

Pillar 2: Non-Canonical RNA Caps (NAD captureSeq)

The 2014 Nature paper introducing NAD captureSeq established NAD as a 5′ cap on a subset of bacterial regulatory RNAs (e.g., RNAI, GadY, GcvB), a field-defining discovery with 262 citations NAD captureSeq Nature paper. Follow-through is rigorous: archaeal NAD-RNA identification in Sulfolobus acidocaldarius and Haloferax volcanii, decapping enzymes (NudC, YvcI), FAD caps, and a critical review honestly flagging method artifacts, stoichiometry gaps, and the need for orthogonal validation in prokaryotic epitranscriptomics Prokaryotic epitranscriptomics review. Notably, his group even reported negative results (no CoAlation marks on S. aureus sRNAs), a marker of epistemic honesty.

Pillar 3: Fluorogenic RNA Aptamers for Super-Resolution Imaging

Building from SRB-2 (contact-mediated quenching, 2013), the group engineered SiRA (silicon rhodamine aptamer, 2019; 142 citations) and RhoBAST (fast-exchange STED-compatible aptamer, Nat. Biotechnol. 2021; 140 citations) RhoBAST Nature Biotechnology. The 2025 co-evolution work refined this further: SiRiuS shows K_D 22 nM, 11.4-fold in-cell turn-on with SiR-5, ~43 nm STED resolution in fixed cells (~94 nm live), validated across four mammalian lines (n≈30–50 cells/sample) with stress-granule imaging and multicolor STED SiRiuS NIR aptamer preprint.

Critical Assessment, Blind Spots, and Confidence

Strengths: rare breadth spanning selection chemistry, structural biology, biophysics, bioinformatics resources (RNAffinityDB), and applied imaging; methodologically generative; transparent about limitations; declared conflicts absent in reviewed works. Weaknesses/blind spots: recent citation velocity is modest (25–28/year in 2024–2025); in-cell performance claims rest on small imaging cohorts (n≈30–50 cells); bacterial FACS-SELEX may not fully capture mammalian context; preprint status of flagship 2025 work limits evidence strength; no primary institution listed in OpenAlex (metadata gap). What would change this assessment: independent replication failures of SiRiuS/RhoBAST in-cell turn-on, or retraction of the NAD-capping paradigm — neither has occurred. Confidence: moderate–high, based on two independent metric databases plus detailed claim-level extraction of two representative papers.

 BGPT Author Review

Scientific Quality

Jäschke combines 25+ years of method-generating work (Diels-Alderase ribozyme, NAD captureSeq, RhoBAST/SiRA aptamers) with structural, biophysical, and cell-biological validation, h-index ~44-46, and multiple high-impact papers (Nature, Nature Biotechnology, JACS). The negative CoAlation result shows epistemic honesty. Deductions: modest recent citation velocity, small in-cell imaging cohorts, and dependence on his own reagents for validation rather than independent replication.

Communication Quality

Reviews are comprehensive and well-organized with explicit limitation discussions; primary papers appear in top journals with clear mechanistic narratives. Some German-language pieces and correction notices suggest occasional editorial sloppiness, and highly technical aptamer work can be dense for non-specialists.

Author Novelty

Field-opening discoveries: first ribozyme catalyzing carbon-carbon bond formation, first demonstration of NAD as a bacterial RNA cap, and NIR light-up aptamers enabling live-cell STED RNA imaging. Multiple first-in-class tools. Deduction: recent aptamer iterations are incremental refinements of his own prior systems.

Scientific Rigor

Strong analytical validation: LC-MS confirmation of NAD caps, crystal structures, SHAPE probing, orthogonally controlled STED resolution measurements, multicolor controls, and honest discussion of sequencing-method artifacts in his own review. Deductions: preprint flagship data not yet peer-reviewed, small cell counts (n=30-50), and self-citation-heavy validation loops typical of tool-development labs.